HDAC 6 inhibitor-based methods for treating cancer
AssigneeSloan-Kettering Institute for Cancer Research
InventorsPaul A. Marks, Weisheng Xu, Mandana Namdar
Life of this patent
Estimating the term…
Abstract
This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide.
Claims14
A method for inducing cell death of a cancer cell, comprising concurrently contacting the cell with (i) a histone deacetylase (HDAC) 6-selective inhibitor selected from the group consisting of tubacin and BAHA, and (ii) a cytotoxic agent selected from the group consisting of suberoylanilide hydroxamic acid (SAHA), doxorubicin, and etoposide, wherein the amounts of the HDAC 6-selective inhibitor and cytotoxic agent, when concurrently contacted with the cell, are effective to increase sensitivity of the cancer cell to the cell death induced by the cytotoxic agent, wherein the cancer cell is a breast cancer cell or a prostate cancer cell.
A method for treating a subject afflicted with cancer, comprising concurrently administering to the subject one of the following combinations of agents selected from the group consisting of:
- (i) tubacin and SAHA;
- (ii) tubacin and doxorubicin;
- (iii) tubacin and etoposide;
- (iv) BAHA and SAHA;
- (v) BAHA and doxorubicin;
- and (vi) BAHA and etoposide, wherein the amounts of each agent in each combination, when concurrently administered, are therapeutically effective to increase sensitivity of cancer cells to SAHA-, doxorubicin-, or etoposide-induced cell death.
Dependencies are inferred from the claim text.